Leukodystrophien und Neurotransmitterstörungen

Zusammenfassung

In diesem Artikel werden beispielhaft zwei Gruppen von angeborenen Erkrankungen dargestellt, die sich vom Säuglingsalter bis zum Erwachsenenalter hin manifestieren können. Die Leukodystrophien sind neurodegenerative Erkrankungen, für die zum Teil experimentelle Therapieansätze entwickelt werden. Für die Gruppe der angeborenen Störungen im Stoffwechsel der biogenen Amine steht bei einigen Defekten mit L-Dopa eine effiziente Therapie zur Verfügung, deren Einsatz so früh wie möglich und lebenslang erfolgen sollte, um irreversible Entwicklungsstörungen und Bewegungsstörungen zu vermeiden.

Summary

In this chapter of a special edition Nervenheilkunde we will describe two illustrative groups of congenital disorders which usually manifest in infancy or childhood but with a range far into adulthood. The first part will describe the group of leukodystrophies which usually follow a neurodegenerative course. Experimental therapies are developed for some of them. In the second part we will describe congenital disorders of neurotransmission concerning the biogenic amines. In most of these L-dopa is a highly efficient therapy which should be started as soon as possible and given life-long in order to avoid irreversible damage to mental and motor development.

Schlüsselwörter

Leukodystrophien - angeborene Neurotransmitterstörungen - L-Dopa-responsive Dystonie

Keywords

Leukodystrophies - congenital neurotransmitter disorders - L-Dopa responsive dystonia

• Literatur

• 1 Anikster Y, Haack TB, Vilboux T. et al. Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet 2017; 100 (02) 257-266.
• 2 Assmann BE, Robinson RO, Surtees RA. et al. Infantile parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology 2004; 62 (10) 1872-1874.
• 3 Bandmann O, Valente EM, Holmans P. et al. Doparesponsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998; 44 (04) 649-656.
• 4 Blau N, Martinez A, Hoffmann GF, Thony B. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. Mol Genet Metab. 2017 epub.
• 5 Brun L, Ngu LH, Keng WT. et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 2010; 75 (01) 64-71.
• 6 Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci 1987; 10: 19-40.
• 7 Carlsson A. A paradigm shift in brain research. Science 2001; 294 (5544): 1021-1024.
• 8 Daubert EA, Condron BG. Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci 2010; 33 (09) 424-434.
• 9 Feldman RS, Meyer JS, Quenzer LF. Principles of Neuropsychopharmacology. In Synaptic structure and function. Sinauer Associates Inc; 1997: 6.
• 10 Friedman J, Roze E, Abdenur JE. et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71 (04) 520-530.
• 11 Gasnier B. The loading of neurotransmitters into synaptic vesicles. Biochimie 2000; 82 (04) 327-337.
• 12 Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294 (5544): 1024-1030.
• 13 Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Human Development 2001; 65 (01) 21-37.
• 14 Hoffmann GF, Assmann B, Brautigam C. et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003; 54 (Suppl. 06) S56-65.
• 15 Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 1990; 13 (03) 301-304.
• 16 Hyland K, Shoffner J, Heales SJ. Cerebral folate deficiency. J Inherit Metab Dis 2010; 33 (05) 563-570.
• 17 Kaufman S, Holtzman NA, Milstien S, Butler LJ, Krumholz A. Phenylketonuria due to a deficiency of dihydropteridine reductase. N Engl J Med 1975; 293 (16) 785-790.
• 18 Kurian MA, Gissen P, Smith M, Heales SJ, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10 (08) 721-733.
• 19 Kurian MA, Li Y, Zhen J. et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. The Lancet Neurology 2011; 10 (01) 54-62.
• 20 Kurian MA, Zhen J, Cheng SY. et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 2009; 119 (06) 1595-1603.
• 21 Leuzzi V, Carducci CA, Carducci CL. et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 2010; 77 (03) 249-257.
• 22 Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009; 32 (03) 333-342.
• 23 Lopez-Laso E, Ochoa-Sepulveda JJ, Ochoa-Amor JJ. et al. Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Cordoba (southern Spain). J Neurol 2009; 256 (11) 1816-1824.
• 24 Mangold S, Blau N, Opladen T. et al. Cerebral folate deficiency: a neurometabolic syndrome?. Mol Genet Metab 2011; 104 (03) 369-372.
• 25 Nestler EJ, Hyman SE, Holtzman DM, Malenka RC. Synaptic transmission. In: Molecular Neuropharmacology. McGraw Hill; 2014
• 26 Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders – clinical advances and future perspectives. Nat Rev Neurol 2015; 11 (10) 567-584.
• 27 Ng J, Zhen J, Meyer E. et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 2014; 137 (Pt 4): 1107-1119.
• 28 Opladen T, Cortes-Saladelafont E, Mastrangelo M. et al. The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders. Mol Genet Metab Rep 2016; 09: 61-66.
• 29 Opladen T, Hoffmann G, Horster F. et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 2011; 26 (01) 157-161.
• 30 Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J In-herit Metab Dis 2012; 35 (06) 963-973.
• 31 Ponzone A, Spada M, Ferraris S, Dianzani I, de Sanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 2004; 24 (02) 127-150.
• 32 Rath M, Korenke GC, Najm J. et al. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease. Journal of the Neurological Sciences 2017; 379: 296-297.
• 33 Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 2013; 368 (06) 543-550.
• 34 Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2011; 33 (03) 195-201.
• 35 Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14: 215-233.
• 36 Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003; 54 (Suppl. 06) S32-45.
• 37 Thöny B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat 2006; 27 (09) 870-878.
• 38 Wassenberg T, Molero-Luis M, Jeltsch K. et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis 2017; 12 (01) 12.
• 39 Werner ER, Blau N, Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438 (03) 397-414.
• 40 Wieland S, Lucki I. Altered behavioral responses mediated by serotonin receptors in the genetically dystonic (dt) rat. Brain Res Bull 1991; 26 (01) 11-16.
• 41 Willemsen MA, Verbeek MM, Kamsteeg EJ. et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133 (Pt 6): 1810-1822.
• 42 Zielonka M, Makhseed N, Blau N, Bettendorf M, Hoffmann GF, Opladen T. Dopamine-responsive growth-hormone deficiency and central hypothyroidism in sepiapterin reductase deficiency. JIMD reports 2015; 24: 109-13.
• 43 Hoffmann GF, Blau N. Congenital Neurotransmitter Disorders: a clinical approach. New York: Nova Science publishers; 2014
• 44 Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders – clinical advances and future perspectives. Nat Rev Neurol 2015; 11 (10) 567-584.